Fexofenadine Hydrochloride

Sanofi is currently in "exclusive talks" with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer healthcare business Opella. The French government has confirmed a commitment from CD&R, based in New York, to ensure that Opella's production facilities in France will remain intact and that there will be no disruption to the supply of drugs to the country, removing a potential obstacle to the deal. Sanofi said the proposed deal valued Opella at 16 billion euros and stressed that CD&R's offer for a 50 percent stake was "binding and fully funded." In addition, French public sector investment bank Bpifrance plans to buy a 2% stake in Opella and take a seat on its board. The deal, expected to close "at the earliest" in the second quarter of next year, will see Sanofi step up its investment in innovative drugs and vaccines and mark the French drugmaker's formal joining the ranks of biopharmaceutical giants Johnson & Johnson, Pfizer and GlaxoSmithKline. "With this transaction, Sanofi will be able to focus even more on providing innovative treatments for patients suffering from debilitating or fatal diseases and viruses, such as RSV, COPD or multiple sclerosis," Sanofi CEO Paul Hudson said in a press release. Analysts at ODDO BHF supported the decision, arguing that a divestiture or partial divestiture of the consumer business would allow Sanofi to reallocate capital to research and business development, and recommended that Sanofi use some of the capital to offset the financial impact of the divestiture through share buybacks. Hudson first floated the idea of spinning off the consumer health division last October. Since then, CD&R and PAI Partners, another private equity giant, have made separate bids for Opella. Earlier this month, Reuters reported that CD&R had made a formal offer to buy 50 percent of Opella's consumer healthcare business. Last week, Sanofi said it was surprised by PAI's move to raise its 200 million euro offer after the deadline. Sanofi's commitment that Opella would continue to operate in France followed a call by French unions for workers to strike on Thursday in protest at the deal. Opella is a leader in over-the-counter medicines, vitamins, minerals and supplements. Its product line includes the well-known antihistamine Allegra, non-opioid painkiller Doliprane, stomach cramping relief Buscopan, Selsun Blue shampoo, and pain treatments Icy Hot and Gold Bond, among others. Opella employs 11,000 people in 100 countries and generated sales of 5.2 billion euros ($5.6 billion) in 2023, accounting for 11% of Sanofi's total revenue. In addition, the company operates 13 production sites and four research and development innovation centers.

Boy Band Icon and Allergy Sufferer Lance Bass Raises Awareness of First-of-its-Kind Navigation Tool Helping People Breathe Cleaner Air NEW YORK, March 5, 2024 /PRNewswire/ -- Allegra, a leading brand in allergy relief, announced today the nationwide launch of Allegra Airways, a groundbreaking navigation tool designed to help outdoor enthusiasts find real-time walking, biking, and running routes with cleaner air based on hyperlocal pollen and air pollution levels on a street-by-street basis. Recent studies show that air pollution alters the pollen structure, releasing more allergens and making pollen more "aggressive." 1,2 These allergens can likely penetrate deeper into your airways, provoking more severe allergy symptoms1,2. What's more concerning is that seasonal allergy symptoms are on the rise, with an estimated 50% of the global population expected to have an allergic disease by 2050.3 "As a brand dedicated to empowering allergy sufferers to live their greatness, Allegra is thrilled to introduce Allegra Airways, a tool that goes beyond traditional solutions, and brings true innovation to the category and deepens our engagement with our consumer," said Jordana Barish, US Allegra Brand Head. "By harnessing hyperlocal data on pollen and air pollution levels, Allegra Airways guides people along cleaner routes, making an invisible problem visible and enabling people to pursue their passions outdoors with confidence." Developed in collaboration with Ambee, a renowned climate and environmental data intelligence company, Allegra Airways enables users to input their start and end destinations at and calculate the cleanest routes based on real-time pollen concentrations and air pollution data from Ambee. "We are thrilled to partner with Allegra on this cutting-edge technology that provides a real time solution for allergy sufferers across the U.S.," explained Jaideep Singh Bachher, co-founder of Ambee. To mark the national launch, Allegra is partnering with boy band legend, Lance Bass, an allergy sufferer, LA outdoor enthusiast, and parent, to raise awareness of the increase in worsening allergy symptoms and how Allegra Airways helps him. "I use Allegra Airways to navigate the cleanest routes as I go about my day in LA including my daily walks with my twins," Lance shared. "I have a lot of exciting projects coming up this year and need to stay on my game and not let my allergy symptoms get in the way." Experience Allegra Airways at SXSW Allegra Airways will debut at SXSW, a global event that sits at the intersection of innovation and culture. On March 9th and 10th, purple Allegra-branded pedicabs fitted with Allegra Airways technology will transport visitors around downtown Austin to find the cleanest route based on real-time data from Ambee where pollen concentrations and air pollution are at its lowest. Join the Allegra Airways community to learn more about how air pollution impacts pollen and how Allegra Airways can help you breathe easy. Visit to find your path to clean air. About Allegra Allegra® Allergy is an oral antihistamine available over the counter at full prescription strength to relieve indoor and outdoor allergy symptoms, including sneezing, runny nose, itchy, watery eyes, and itchy nose or throat. It provides fast, non-drowsy relief that starts in just one hour and stays strong for 24 hours. Allegra can be used by adults and children 2 years of age and older. For more information, visit . Sanofi Consumer Healthcare, US, the makers of Allegra, was recently B Corp certified. This distinction highlights the company's commitment for an inclusive and regenerative economy through its social and environmental impact. Sanofi US CHC believes that healthier people and a healthy planet go hand in hand. About Ambee Ambee is a climate and environmental intelligence technology company that provides real-time and accurate data to empower businesses, individuals and communities to make informed decisions for better outcomes. Media Contact Tia Harris [email protected] (312) 515 – 0518 Annesi-Maesano I;Maesano CN;Biagioni B;D'Amato G;Cecchi L; "Call to Action: Air Pollution, Asthma, and Allergy in the Exposome Era." The Journal of Allergy and Clinical Immunology, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/34238507/. D'Amato, G.; Annesi-Maesano, I.; Biagioni, B.; Lancia, A.; Cecchi, L.; D'Ovidio, M.C.; D'Amato, M. New Developments in Climate Change, Air Pollution, Pollen Allergy, and Interaction with SARS-CoV-2. Atmosphere 2023, 14, 848. Cecchi L, D'Amato G, Annesi-Maesano I. External exposome and allergic respiratory and skin diseases. J Allergy Clin Immunol 2018;141:846-57. SOURCE Allegra